Top 50 Medical Device Startup Investors in Sweden in November 2024

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

Heartcore Capital invests in companies re-enchanting the world through technology.

Sophia Bendz - Partner @ Cherry Ventures

Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.

We help great minds unleash their full potential!

Bonnier Capital is the investment division of the Bonnier Group. Since 2016, we invest in promising companies in structurally growing industries and have become a reliant investment partner to companies and funds of various sizes.

Tim Jackson is the Founder, CEO, General Partner & Partner of Walking Ventures & he attended University of Oxford in in 1983.

KHP Ventures is an investment firm that provides innovative ideas for healthcare.

Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

LU Innovation is the hub for innovation and commercialisation at Lund University. They work with the University's researchers and students to bring benefit and growth to society.Their goal and mission is to contribute to increased growth in Sweden by ensuring knowledge and research from Lund University benefit society.By supporting anddeveloping research findings with researchers and students they work to lead more ideas to company formations and/or licensing deals.Services for all researchers and students:- Business advice – support and advice - Verification support – VFT- Market and IP screening – comprehensive survey of markets, competitors and patent situationThe services are freely available to researchers and students at all faculties at Lund University.An important part of the work of LU Innovation is providing commercialisation support to individual researchers or students. As well as business developers with many years of experience from both research and business, they have patent engineers, a communications officer and a lawyer who can help with the process. LU Innovation has two sections: one a part of the public authority and the other a holding company, which function as one unit with a joint mission and joint management.LU Innovation is led by the board of the holding company and the steering group of the public authority section. The members of the two bodies are identical - see board members. The operations are led by Director of Innovation Linus Wiebe, who is both MD of the holding company and head of the public authority section.

Conor Venture Partners is a new breed technology venture capital fund and management company. Conor invests in early-stage companies originating from Nordic and Baltic countries. Investment areas include information and communications technology, embedded software, semiconductor technology, electronics, new materials and optics.

Laurent Leksell

Maria Rankka

Fibonacci Growth Capital is a venture capital investment firm.

Springboard Health Angels is a Berlin based Angel group to invest in early stage Digital Health startups

Crosslight Partners is a growth equity firm. The firm invests in the environment, healthcare, impact, and technology sectors across Europe.

Sting – Stockholm Innovation & Growth enables talented people to turn their ideas into sustainable businesses. The support they offer includes qualified coaching in business development, a business angel network, a venture capital fund, a recruitment service, and an international network of investors, business contacts and experts. Itcontribute to the success of Sweden’s future technology companies by helping them to grow and compete internationally.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Private Investment Company

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totaling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but on bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totaling €660 million. EQT Ventures III launched in 2022, with commitments totaling €1.1 billion, making it the biggest European Venture Capital fund committed to early-stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris, and San Francisco, taking a locals-with-locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has a data-driven approach and has driven more than $100 million in portfolio company investments.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

AngCell Ventures is a venture capital investment firm.

Emil Sjödin has been serving as Chief Executive Officer at RefinedWiki since December 2013.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Colibri Ventures invest in early-stage life science companies and help accelerate their innovations into commercial products.

Founder DLL-files.com - the worlds most popular website for downloading dll files Angel investor since 2008

Headline is a Venture Capital firm actively on the ground in 7 cities around the world. We invest across categories and geographies, leading rounds at every stage. Once we commit to a team, we go to the ends of the earth to make their success global.

Sweet is the King.com (Candy Crush) founders' evergreen investment fund. We are passionate about funding the next generation of entrepreneurs.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Alexander Hars - Board member @ Zalster

Ackra Invest AB is a venture capital and private equity firm specializing in late venture, growth capital and turnaround investments. The firm does not have a sector preference and seeks to invest in small and middle sized companies based in Norrland; the Northern region of Sweden. It does not provide loans or invest in seed or early venture. Thefirm takes minority stakes, between 10 percent and 49 percent and invests between SEK1 million ($0.13 million) and SEK8 million ($1.02 million). It invests in equity or convertible loans and can perform co-investments. The firm seeks to exit its investments within seven years. Ackra Invest AB was founded in 2005 and is based in Skellefteå, Sweden.

Incos Invest is a venture capital firm specializing in start-up and early-stage investments. The firm seeks to make investments in companies operating in the industries of cosmetics, perfumes, travel and tourism, real estate, e-commerce, IT, and software development. The company is headquartered in Skane Lan, Sweden.

Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Loop Capital - Client-focused investment banking, brokerage and advisory services

KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.

Kirin Holdings manufactures and sells alcoholic and non-alcoholic beverages, and pharmaceuticals, and bio-chemicals in Japan and internationally. It operates through four segments: Japan Integrated Beverages Business, Oceania Integrated Beverages Business, Other Overseas Integrated Beverages Business, and Pharmaceuticals and Bio-Chemicals Business.Kirin Holdings' products include beer, happo-shu, wine, whiskey, spirits, soft drinks, dairy products, fruit juices, and other products. It also produces and sells pharmaceutical products, biochemical products, and other products. Moreover, Kirin Holdings engages in the livestock feed and theme park businesses; and management and operation of a chain of Kirin City beer pubs; manufacture and sale of amino acids and nucleic acids for pharmaceutical and industrial use bulk pharmaceuticals, as well as margarine, jams, and honey. Further, it is involved in the manufacture and sale of Coca-Cola products and other soft drinks, as well as sake; and manufacture and supply of Four Roses bourbon. Kirin Holdings has a strategic collaboration with Mitsui and Onegevity Health for launching a testing system in Japan, as well as to develop nutritional products. Kirin Brewery began operation in 1907 became Kirin Holdings in July 2007, with its headquarters in Tokyo in Japan.

Daniel Andersson

Walking Ventures is a seed fund which invests in early-stage Internet and other technology startups based in Europe. The fund is a private vehicle controlled by Tim Jackson, a leading figure in the European technology scene as a venture capitalist, entrepreneur, angel investor, commentator and technology journalist.

The primary responsibilities of the group are to source, qualify, and invest in technology related companies. Our major investment areas include semiconductors, materials, mobile service, internet, software, security, enterprise solutions, bio engineering & medical, while potential investment subjects range from early-stage startups to pre-IPOcompanies. Currently, the group has over $1.8B under management and invests $250M annually.Samsung Ventures was founded on October 8, 1999, and is based in Seoul, South Korea.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

Curus invest and acquire to enable the future's leading innovations and companies in health and medicine.

Boel Rydenå-Swartling

Per Båtelson